The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Medincell (Paris:MEDCL): This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or ...

This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell ...

The Global Offering is also aimed at retail investors via PrimaryBid platform, exclusively in France. Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO ® ...